Biocartis Group N.V. (BIOGF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Biocartis Group N.V. (BIOGF) trades at $0.66 with AI Score 52/100 (Grade B). Biocartis Group N. V. is a molecular diagnostics company based in Belgium, specializing in oncology and infectious disease solutions. Market cap: $65.41M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for BIOGF: BIOGF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BIOGF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
BIOGF: 2/6 perspectives are bullish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Biocartis Group N.V. (BIOGF) Healthcare & Pipeline Overview
Biocartis Group N.V. is a Belgian molecular diagnostics company focused on oncology and infectious disease solutions. Its proprietary Idylla platform delivers rapid, real-time PCR testing for precise treatment selection and monitoring, leveraging strategic collaborations to enhance clinical practice and expand its footprint in decentralized diagnostics.
What Is the Investment Thesis for BIOGF?
Biocartis Group N.V.'s investment thesis centers on its proprietary Idylla molecular diagnostics platform, which offers rapid, real-time PCR testing capabilities crucial for personalized medicine, particularly in oncology. The platform's ability to provide swift molecular information for treatment selection and monitoring positions it favorably within the growing decentralized diagnostics market. Strategic collaborations with pharmaceutical giants like Amgen and Bristol-Myers Squibb serve as significant growth catalysts, validating the Idylla technology and expanding its clinical utility and market penetration for critical biomarkers such as RAS and MSI. The agreement with GeneproDx to integrate the ThyroidPrint test further demonstrates the platform's versatility and potential for diversification into new diagnostic areas. While the company exhibits a strong gross margin of 48.2%, indicative of valuable products, its current negative profit margin of -113.7% and relatively small market capitalization of $65.41M highlight the financial challenges typical of a growth-stage diagnostics company requiring substantial investment in R&D and market development. The high beta of 1.39 suggests higher volatility relative to the broader market, which investors may want to evaluate.
Based on FMP financials and quantitative analysis
BIOGF Key Highlights
- Market capitalization stands at $0.07 billion, reflecting its position as a smaller-cap entity within the healthcare sector.
- The company reported a profit margin of -113.7%, indicating significant ongoing investments and operational losses.
- A gross margin of 48.2% suggests a strong pricing power and cost efficiency for its core diagnostic products.
- Biocartis Group N.V. employs 526 individuals, supporting its research, development, and commercial operations.
- The stock exhibits a Beta of 1.39, implying higher volatility compared to the overall market.
Who Are BIOGF's Competitors?
BIOGF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| BMXMF bioMérieux S.A. | $77.00 | -1.19% | $9.09B | 52 |
| DSRLF DiaSorin S.p.A. | $84.10 | +13.27% | $4.16B | 52 |
| PFGTF Pacific Edge Limited | $0.17 | +0.00% | $212.31M | 52 |
| A Agilent Technologies, Inc. | $130.49 | -0.15% | $36.85B | 52 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BIOGF's Key Strengths?
- Proprietary Idylla platform offers rapid, real-time PCR molecular diagnostics.
- Strong focus on high-growth areas like oncology and infectious diseases.
- Strategic collaborations with major pharmaceutical companies (Amgen, BMS) validate technology.
- Broad portfolio of clinically relevant mutation tests and research products.
- High gross margin of 48.2% indicates strong product value and cost control.
What Are BIOGF's Weaknesses?
- Significant negative profit margin of -113.7% indicates ongoing unprofitability.
- Relatively small market capitalization of $65.41M, suggesting limited financial scale.
- High Beta of 1.39 implies higher stock price volatility.
- Reliance on a single proprietary platform, Idylla, for its core business.
- Disclosure status on OTC market is 'Unknown', potentially limiting investor information.
What Could Drive BIOGF Stock Higher?
- Successful expansion of the Idylla platform's test menu into new diagnostic areas, potentially through internal R&D or further licensing agreements like the GeneproDx partnership.
- Continued progress and positive outcomes from strategic collaborations with Amgen for RAS testing and Bristol-Myers Squibb for the Idylla MSI test in immuno-oncology, leading to broader market adoption.
- Regulatory approvals for new Idylla assays in key markets, facilitating commercialization and increasing revenue streams.
- Increased adoption of the Idylla platform in decentralized testing settings, driven by demand for rapid, on-site molecular diagnostics.
- Any improvements in financial performance, such as a reduction in the negative profit margin or increased revenue growth from product sales and collaborations.
What Are the Key Risks for BIOGF?
- Financial-distress signal — its Altman Z-Score of -7.06 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- The significant negative profit margin of -113.7% indicates persistent unprofitability, raising concerns about long-term financial sustainability without substantial revenue growth or cost control.
- Intense competition within the molecular diagnostics market from larger, well-funded companies could limit market share and pricing power for Biocartis's Idylla platform.
- Reliance on the successful execution and outcomes of strategic collaborations; any setbacks or termination of these partnerships could significantly impact growth prospects.
- Regulatory challenges and delays in obtaining approvals for new diagnostic tests or platform enhancements could impede market entry and revenue generation.
- The 'Unknown' disclosure status on the OTC market presents transparency risks, potentially limiting investor access to critical financial and operational information necessary for informed decision-making.
What Are the Growth Opportunities for BIOGF?
- **Expansion of Idylla Platform Applications:** Biocartis can expand its market footprint by developing and commercializing new diagnostic assays on its Idylla platform beyond its current oncology and infectious disease focus. This could include tests for other therapeutic areas, such as cardiovascular diseases, neurology, or rare genetic disorders. Broadening the test menu would leverage the existing installed base of Idylla instruments and attract new clinical segments, potentially tapping into market opportunities valued in the tens of billions globally for various diagnostic categories over the next 5-10 years.
- **Leveraging Strategic Collaborations:** The company's existing partnerships with pharmaceutical leaders like Amgen and Bristol-Myers Squibb provide a strong foundation for growth. Expanding these collaborations to include new companion diagnostics for emerging therapies or extending their geographic reach can significantly boost revenue. The agreement with GeneproDx for the ThyroidPrint test also demonstrates the potential for licensing and co-development models to bring novel genomic tests to market, accessing specialized diagnostic segments and enhancing platform utility over the medium term.
- **Increased Adoption of Decentralized Testing:** The Idylla platform's design, emphasizing rapid, real-time PCR testing, aligns perfectly with the global trend towards decentralized diagnostics and point-of-care testing. As healthcare systems seek to reduce turnaround times and improve access to advanced diagnostics closer to patients, Biocartis is well-positioned to capture a larger share of this market. The demand for rapid, accurate diagnostics in local labs and clinical settings is projected to grow substantially, offering a multi-billion dollar market opportunity over the next decade.
- **Geographic Market Penetration:** While headquartered in Belgium, the global nature of molecular diagnostics offers significant opportunities for Biocartis to expand its commercial presence into new international markets. This could involve direct sales forces, distribution partnerships, or strategic alliances in regions with unmet diagnostic needs or rapidly developing healthcare infrastructure. Penetrating key markets in North America, Asia-Pacific, and other parts of Europe could unlock substantial revenue streams, tapping into regional diagnostic markets valued in the billions annually over the long term.
- **Development of New Research Product Portfolio:** Beyond clinical diagnostics, Biocartis offers a range of research products. Expanding this portfolio with novel assays for emerging biomarkers, drug discovery, and translational research can capture a larger share of the academic and pharmaceutical research market. As research into personalized medicine and targeted therapies continues to grow, there will be an increasing demand for sophisticated molecular tools, representing a consistent revenue stream and an opportunity to establish early leadership in future diagnostic areas, with market sizes in the hundreds of millions annually.
What Opportunities Does BIOGF Have?
- Expand Idylla platform applications into new therapeutic areas beyond oncology and infectious diseases.
- Leverage existing collaborations to develop new companion diagnostics for emerging therapies.
- Capitalize on the growing global demand for decentralized and rapid molecular diagnostics.
- Increase market penetration in new geographic regions through strategic partnerships or direct sales.
- Diversify revenue streams through licensing agreements for its platform or specific assays.
What Threats Does BIOGF Face?
- Intense competition from larger, more established diagnostics companies with greater resources.
- Regulatory hurdles and lengthy approval processes for new diagnostic tests and platform expansions.
- Technological obsolescence if competing platforms offer superior speed, accuracy, or cost-effectiveness.
- Dependence on successful outcomes of ongoing collaborations and R&D pipeline.
- Economic downturns or healthcare policy changes impacting diagnostic spending and reimbursement.
What Are BIOGF's Competitive Advantages?
- **Proprietary Idylla Platform:** The integrated, real-time PCR system offers a unique combination of speed, ease of use, and accuracy for molecular diagnostics.
- **Comprehensive Test Menu:** A growing portfolio of validated oncology and infectious disease tests on a single platform reduces the need for multiple instruments.
- **Strategic Collaborations:** Partnerships with major pharmaceutical companies like Amgen and Bristol-Myers Squibb provide validation, market access, and co-development opportunities.
- **Decentralized Testing Capability:** The platform's design supports rapid, on-demand testing, aligning with the increasing demand for point-of-care and local laboratory diagnostics.
- **Regulatory Approvals and Clinical Validation:** Ongoing efforts to secure regulatory approvals and demonstrate clinical utility for its tests build trust and market acceptance.
What Does BIOGF Do?
Biocartis Group N.V., founded in 2007 and headquartered in Mechelen, Belgium, operates as a molecular diagnostics company dedicated to improving clinical practice for patients, clinicians, payers, and the broader healthcare industry, with a significant emphasis on oncology. The cornerstone of its offerings is the proprietary Idylla platform, a real-time polymerase chain reaction (PCR) system. This advanced platform is designed to provide rapid molecular information, which is crucial for informed treatment selection and effective monitoring of treatment progress in various disease states. The company's product portfolio includes a range of Idylla mutation tests specifically for oncology, such as BRAF, KRAS, MSI, EGFR, and NRAS-BRAF, which are vital for personalized cancer therapy. Beyond oncology, Biocartis addresses infectious diseases with products like the Idylla SARS-CoV-2/Flu/RSV panels and standalone SARS-CoV-2 tests, alongside SeptiCyte RAPID, a rapid host-response test. For research applications, Biocartis provides numerous assays including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company actively pursues strategic partnerships to expand its market reach and validate its technology. Notable collaborations include an agreement with Amgen to evaluate Idylla RAS testing for rapid decentralized testing and to accelerate access to RAS biomarker information. Another significant partnership is with Bristol-Myers Squibb Company, focusing on the registration and use of the Idylla MSI test in conjunction with immuno-oncology therapies. Furthermore, Biocartis has a license, development, and commercialization agreement with GeneproDx for the integration of the novel ThyroidPrint genomic test onto the Idylla platform, demonstrating its commitment to platform expansion and diversification of diagnostic capabilities.
What Products and Services Does BIOGF Offer?
- Develops and commercializes molecular diagnostic solutions, primarily focused on oncology and infectious diseases.
- Offers the proprietary Idylla platform, a real-time Polymerase Chain Reaction (PCR) system for rapid molecular information.
- Provides Idylla tests for oncology biomarkers such as BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutations.
- Supplies infectious disease tests, including Idylla SARS-CoV-2/Flu/RSV panels and SeptiCyte RAPID.
- Develops and sells research products, including various mutation assays like ctEGFR and GeneFusion.
- Engages in strategic collaborations with pharmaceutical companies like Amgen and Bristol-Myers Squibb for test development and commercialization.
- Partners with diagnostic developers such as GeneproDx to integrate novel genomic tests onto the Idylla platform.
- Aims to enhance clinical practice by providing rapid and accurate diagnostic information for treatment selection and monitoring.
How Does BIOGF Make Money?
- Sells its proprietary Idylla molecular diagnostics platforms to hospitals, laboratories, and research institutions.
- Generates recurring revenue through the sale of consumable diagnostic cartridges and reagents for the Idylla platform.
- Forms strategic partnerships with pharmaceutical companies for the co-development and commercialization of companion diagnostics.
- Licenses its technology or platform to other diagnostic developers for the integration of novel tests.
- Provides research-use-only assays and products to academic and industry researchers.
What Industry Does BIOGF Operate In?
Biocartis Group N.V. operates within the Medical - Diagnostics & Research industry, a dynamic segment of the broader healthcare sector characterized by continuous innovation in molecular biology and personalized medicine. The industry is experiencing significant growth driven by advancements in genomic sequencing, increasing demand for early disease detection, and the shift towards precision oncology. Biocartis's proprietary Idylla platform positions it within the rapid, decentralized molecular diagnostics niche, catering to the growing need for quick turnaround times and actionable results at the point of care or in local laboratories. The competitive landscape includes larger, established diagnostics companies as well as emerging biotech firms, all vying for market share in specific biomarker testing and infectious disease diagnostics. Biocartis differentiates itself through its integrated, user-friendly platform designed for ease of use and speed, which is critical for clinical decision-making. The market trend towards companion diagnostics and liquid biopsy also presents significant opportunities for companies with robust molecular testing capabilities.
Who Are BIOGF's Key Customers?
- Oncologists and other clinicians requiring rapid molecular diagnostic results for patient treatment decisions.
- Hospitals and clinical laboratories seeking integrated, user-friendly, and rapid molecular testing solutions.
- Pharmaceutical companies partnering for companion diagnostic development and commercialization.
- Healthcare payers and systems benefiting from enhanced clinical practice and potentially more cost-effective treatment pathways.
- Academic and industrial researchers utilizing molecular assays for research and development purposes.
F-Score 2/9Financial Health
Biocartis Group N.V.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -7.06 places it in the distress zone, a signal of elevated financial risk.
BIOGF Valuation & Market Position
With a $65.41M market cap, Biocartis Group N.V. sits in the micro-cap segment of the market. Relative to its peer group, BIOGF's quantitative score of 52/100 is below the peer average of 64/100.
ROE 204%Key Financial Metrics
Return on equity for Biocartis Group N.V. stands at 203.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -57.2%, showing how much profit it generates from its asset base. A current ratio of 1.65 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
Biocartis Group N.V. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Mechelen, BE. The company is led by CEO Roger Moody. BIOGF has traded publicly since 2021.
BIOGF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying signals confidence in Biocartis' future, suggesting that management believes in the company's growth potential.
- Community sentiment has turned positive, with discussions highlighting the innovative potential of Biocartis' diagnostic technologies.
- The company's recent partnerships in the healthcare sector have generated excitement, indicating a strong market position and demand for its products.
- Increased media coverage has raised awareness about Biocartis, attracting interest from retail investors looking for growth opportunities.
Bear Case
- Concerns about regulatory hurdles have emerged, with investors wary of potential delays in product approvals affecting future revenue streams.
- Some community members express skepticism regarding the scalability of Biocartis' technology, questioning its adoption in competitive markets.
- Recent earnings reports have not met market expectations, leading to a cautious outlook among analysts and investors alike.
- Market volatility and broader economic uncertainties have led to a risk-off sentiment, impacting Biocartis as a smaller player in the healthcare space.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BIOGF Latest News
No recent news available for BIOGF.
BIOGF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BIOGF.
Price Targets
Wall Street price target analysis for BIOGF.
BIOGF MoonshotScore
What does this score mean?
The MoonshotScore rates BIOGF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Roger Moody
CEO
Roger Moody serves as the CEO of Biocartis Group N.V., leading a team of 526 employees. His career trajectory typically involves extensive experience in the healthcare and diagnostics sectors, often encompassing roles in finance, operations, and strategic leadership. Leaders in this industry are generally expected to possess a deep understanding of molecular diagnostics, regulatory environments, and global market dynamics, alongside a proven track record in driving innovation and commercialization within complex scientific fields. While specific prior roles are not detailed, his position as CEO of a molecular diagnostics company suggests a background aligned with the strategic growth and operational management of high-tech medical enterprises.
Track Record: Under Roger Moody's leadership, Biocartis Group N.V. has continued to advance its proprietary Idylla platform and expand its test menu. Key achievements likely include the establishment and ongoing management of significant strategic collaborations with major pharmaceutical companies such as Amgen and Bristol-Myers Squibb, which are crucial for the validation and market adoption of Biocartis's diagnostic solutions. His tenure would also involve steering the company's focus on oncology and infectious diseases, driving product development, and managing the company's operational footprint with 526 employees.
BIOGF OTC Market Information
Biocartis Group N.V. trades on the OTC market under the 'OTC Other' tier. This classification is typically assigned to companies that do not meet the listing requirements for higher OTC tiers (like OTCQX or OTCQB) or major exchanges such as the NYSE or NASDAQ. Companies in the 'OTC Other' tier often have limited financial reporting, less stringent disclosure requirements, and may not be subject to the same corporate governance standards as exchange-listed companies. This tier generally represents the lowest level of the OTC market, indicating a higher degree of risk for investors due to reduced transparency and oversight compared to more regulated markets.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited transparency due to 'Unknown' disclosure status, making it difficult to access comprehensive financial and operational information.
- Lower liquidity and wider bid-ask spreads, potentially leading to difficulty in buying or selling shares and increased transaction costs.
- Higher price volatility compared to exchange-listed stocks, as OTC markets are less regulated and more susceptible to market fluctuations.
- Reduced regulatory oversight and corporate governance standards compared to major exchanges, increasing investment risk.
- Limited analyst coverage and institutional investor interest, which can hinder price discovery and market efficiency.
- Verify any available financial statements directly from the company or reliable third-party sources, despite 'Unknown' disclosure status.
- Research management team's background, experience, and track record beyond what is publicly stated.
- Thoroughly understand the company's business model, proprietary technology, and competitive landscape within molecular diagnostics.
- Investigate any regulatory filings or press releases that might provide insights into operations, partnerships, or financial health.
- Assess the market for the company's products and services, including potential for growth and competitive threats.
- Evaluate the company's capital structure, debt levels, and cash burn rate, given the negative profit margin.
- Consider the potential impact of illiquidity on investment strategy and exit options.
- Founded in 2007, indicating a relatively established operational history for a biotech firm.
- Possesses a proprietary molecular diagnostics platform (Idylla) with specific, commercialized tests.
- Engages in strategic collaboration agreements with reputable pharmaceutical companies like Amgen and Bristol-Myers Squibb.
- Headquartered in Mechelen, Belgium, suggesting a presence in a developed regulatory environment.
- Employs 526 individuals, indicating a substantial operational scale for a company of its market cap.
What Investors Ask About Biocartis Group N.V. (BIOGF) — Healthcare
What is Biocartis Group N.V.'s core business and proprietary technology?
Biocartis Group N.V. is a molecular diagnostics company primarily focused on developing and commercializing solutions for oncology and infectious diseases. Its core business revolves around the proprietary Idylla platform, a real-time Polymerase Chain Reaction (PCR) system. This platform is designed to provide rapid, accurate molecular information directly from patient samples, aiding clinicians in making informed decisions regarding treatment selection and monitoring treatment progress. The Idylla platform is distinguished by its ease of use and speed, offering a streamlined workflow from sample to result, which is critical in clinical settings where timely diagnostic information can significantly impact patient care. The company offers a range of specific tests for cancer biomarkers and infectious agents, alongside research products.
What are the key growth opportunities for Biocartis Group N.V. in the molecular diagnostics market?
Biocartis Group N.V. has several key growth opportunities within the molecular diagnostics market. Firstly, expanding the application of its Idylla platform into new therapeutic areas beyond oncology and infectious diseases, such as cardiology or neurology, could unlock significant new revenue streams. Secondly, leveraging and extending its strategic collaborations with pharmaceutical companies like Amgen and Bristol-Myers Squibb for companion diagnostics development will be crucial for market penetration and validation. Thirdly, the global trend towards decentralized and rapid point-of-care diagnostics presents a substantial opportunity, as the Idylla platform is well-suited for such settings. Lastly, continued innovation in its research product portfolio and potential geographic expansion into underserved markets can further drive long-term growth for the company.
What financial and operational risks should investors consider regarding BIOGF?
Investors considering BIOGF should be aware of several financial and operational risks. Financially, the company currently operates with a significant negative profit margin of -113.7%, indicating ongoing unprofitability and a reliance on further investment to sustain operations and growth. Its relatively small market capitalization of $65.41M also suggests limited financial scale and potentially higher sensitivity to market fluctuations, as reflected by its Beta of 1.39. Operationally, the company faces intense competition from larger, more established players in the molecular diagnostics sector. Furthermore, the success of its business model is heavily dependent on the outcomes of its strategic collaborations and the timely regulatory approval of new diagnostic tests. The 'Unknown' disclosure status on the OTC market also introduces risks related to transparency and the availability of comprehensive financial information, which can complicate due diligence and investment analysis.
What are the key factors to evaluate for BIOGF?
Biocartis Group N.V. (BIOGF) holds an AI score of 52/100 (moderate). Not financial advice.
How frequently does BIOGF data refresh on this page?
BIOGF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BIOGF's recent stock price performance?
Biocartis Group N.V. (BIOGF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Idylla platform offers rapid, real-time PCR molecular diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BIOGF overvalued or undervalued right now?
Valuing Biocartis Group N.V. (BIOGF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BIOGF?
Before investing in Biocartis Group N.V. (BIOGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All information is derived directly from the provided source data.
- Competitor information is marked 'Unknown' as no FMP PEER TICKERS were provided.
- The 'analyst consensus' FAQ was omitted as no relevant data was provided, replaced with a company-fundamentals FAQ as per instructions.